Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic

Authors
Category Primary study
JournalMult. Scler. J. Exp. Transl. Clin.
Year 2020
This article has no abstract
Epistemonikos ID: 20c84ee2236723c3f9354a2e1598c9e81b4dadf9
First added on: Oct 20, 2020